Form 4: Metsera CEO Converts Equity Post-Pfizer Merger

Metsera, Inc. President and CEO, Christopher Whitten Bernard, converted his equity holdings into cash and contingent value rights following the company's acquisition by Pfizer Inc.

Summary

• Metsera, Inc. completed a merger with Pfizer Inc. subsidiary, Mayfair Merger Sub, Inc., on November 13, 2025, making Metsera a wholly-owned subsidiary of Pfizer.
• Christopher Whitten Bernard, President and CEO, converted his direct and indirect equity holdings in Metsera as a result of the merger.
• Each outstanding share of common stock was converted into $65.60 in cash (the 'Closing Amount') plus one contractual contingent value right (CVR).
• Bernard's 21,250 directly owned common shares were converted into cash and CVRs.
• His indirect beneficial ownership of 12,767,462 common shares, held by Population Health Partners, L.P. and Population Health GP LLC, was also converted.
• His 21,250 restricted stock units (RSUs), granted on November 12, 2025, were cancelled and converted into cash equal to the Closing Amount multiplied by the number of shares subject to the RSU, plus a corresponding number of CVRs, subject to the original vesting schedule.
• His stock options (348,750 units with an exercise price of $29.25 and 1,702,328 units with an exercise price of $4.33) were cancelled.
• Option holders received cash equal to the product of (Closing Amount exercise price) multiplied by the number of shares, plus one CVR for each share, with unvested portions subject to original vesting schedules and a one-year continued service condition with Pfizer or its subsidiaries.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, resulting in a cash payout for equity holders and the potential for additional value through CVRs. While the company is no longer independent, the terms appear favorable for the reporting person's equity conversion.

Positives

• The Reporting Person received a significant cash payout for common stock and vested equity awards at $65.60 per share/unit.
• There is potential for additional cash payments through Contingent Value Rights (CVRs) upon the achievement of specified milestones.
• Unvested equity awards (RSUs and options) were converted into cash and CVRs, maintaining their value subject to vesting conditions.

Negatives

• Metsera, Inc. is no longer an independent publicly traded company, resulting in the cessation of direct equity ownership for shareholders.
• Contingent Value Rights (CVRs) are not guaranteed and depend on future milestone achievements.
• Unvested cash and CVR payments for former stock options require continued service with Pfizer or its subsidiaries for one year post-merger.

Risks

• The value of Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specific, undisclosed milestones.
• Failure to meet continued service requirements with Pfizer or its subsidiaries could result in forfeiture of unvested cash payments and CVRs related to former stock options.

Future Outlook

The future outlook for former Metsera shareholders and equity holders includes potential additional cash payments through Contingent Value Rights (CVRs) upon the achievement of certain specified milestones. For the reporting person, unvested cash payments and CVRs related to former stock options are contingent on continued service with Pfizer or its subsidiaries through the first anniversary of the merger.

Management Comments

• "As a member of PHP GP LLC, the Reporting Person may be deemed to share the power to direct the disposition and vote of the PHP Shares."
• "The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that it is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."

Industry Context

This filing reflects the typical outcome of an acquisition where a public company becomes a wholly-owned subsidiary. Executives' equity holdings are converted into cash and, often, contingent value rights to align incentives for post-merger performance or to bridge valuation gaps. This is a common mechanism in pharmaceutical or biotech mergers, where future drug development or regulatory milestones can significantly impact value.

Comparison to Industry Standards

• The conversion of common stock into a fixed cash amount plus Contingent Value Rights (CVRs) is a standard mechanism in M&A transactions, particularly in industries like pharmaceuticals where future value is tied to specific development or regulatory milestones. For example, similar CVR structures have been used in acquisitions such as Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of MyoKardia, where additional payments were contingent on clinical trial success or regulatory approvals.
• The cash payout for options, calculated as the difference between the merger price and the exercise price, is also standard practice.
• The requirement for continued service for unvested equity payouts is a common retention strategy post-acquisition.

Management Changes

Corporate Governance

Related Party Transactions

• 12,639,787 shares of Common Stock are held of record by Population Health Partners, L.P. and 127,675 shares by Population Health GP LLC. The Reporting Person, as a member of PHP GP LLC (the sole general partner of PHP LP), may be deemed to share power to direct disposition and vote of these shares.

Stakeholder Impact

• Shareholders received a fixed cash amount and Contingent Value Rights (CVRs) for their shares.
• Employees (including the reporting person) with unvested equity awards have continued service requirements with Pfizer or its subsidiaries to receive full payouts.

Next Steps

• Achievement of specified milestones for Contingent Value Rights (CVRs) to trigger additional payments.
• Continued service of the reporting person with Pfizer or its subsidiaries through the first anniversary of the merger for full vesting of unvested cash payments and CVRs from former stock options.

Key Dates

Keywords

Metsera, Pfizer, Merger, Acquisition, Form 4, Insider Transaction, Equity Conversion, Contingent Value Rights, CVR, Stock Options, Restricted Stock Units, MTSR, Corporate Governance, Beneficial Ownership